The analysis of a Phase III trial of panitumumab (PICCOLO) reported similar PFS outcomes between rectal and right-sided colon cancers in RAS-wt mCRC patients and mentioned that the benefit of anti-EGFR agents against rectal cancers may be overestimated [37]. This evidence concerns the gene EGFR and malignant colon neoplasm.